Hyman Schipper received his MD and PhD degrees in neuroendocrinology at McGill University in 1982. He completed an Internal Medicine Residency at the Sir Mortimer B. Davis Jewish General Hospital (McGill; 1982-4), a Residency in Neurology at Columbia University (1984-7) and a Fellowship in Endocrinology at Tufts University (1987-8). Dr. Schipper is currently tenured Professor of Neurology and Medicine (Geriatrics) at McGill University, staff neurologist at the Jewish General Hospital, and consultant at other Montreal institutions. He is founding director of the Centre for Neurotranslational Research and the Biomedical Redox Laboratory at the Jewish General Hospital. In 2005, he became founding scientist and medical director (neurosciences) of Molecular Biometrics LLC, a company developing metabolomics-based diagnostic technologies in neurodegenerative diseases and assisted reproduction.

Dr. Schipper’s long-standing research interests are in the fields of oxidative stress, brain aging and neurodegenerative diseases. Since 1990, his laboratory has contributed evidence implicating heme oxygenase-1 (HO-1) and iron-containing astroglia in CNS senescence and free radical-related neurodegenerative disorders. Dr. Schipper has published over 140 primary and review articles on various aspects of the redox neurosciences and related topics and is an inventor on 11 patents. He serves on the editorial board of the Journal of Neurochemistry, is an internal examiner for the Canadian Institutes of Health Research, and is a member of 14 professional societies. At McGill University and the Jewish General Hospital, Dr. Schipper provides basic and clinical teaching in the neurosciences and coordinates an interdisciplinary course on Free Radical Biomedicine in the Faculty of Science.